Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yoshida, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshida, T
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology Pages 774-777

News
News from Japan
Awards
Cancer Statistics Digest
Viewing the News from Abroad
Announcements
News

News from Japan

First Cancer Gene Therapy in Japan

The Research Hospital of the Institute of Medical Science, the University of Tokyo (IMSUT) (Director, Professor Shigetaka Asano) announced on October 5 that it had started the first clinical trial of cancer gene therapy in Japan in collaboration with several other institutions.


Figure 1. Professor Shigetaka Asano.

According to Associate Professor Kenzabro Tani, who is in charge of the clinical trial, the first patient is a 60–year–old male with renal cell carcinoma and will be followed by four other patients with the same cancer. The strategy is an immune gene therapy originally proposed by Dr Richard Mulligan’s group: a surgically resected renal tumor is put into a culture, and the cells are transduced ex vivo with a retrovirus vector harboring a GM–CSF (granulocyte–macrophage colony stimulating factor) expression unit. . . . [Full Text of this Article]

Awards

Cancer Statistics Digest

Viewing the News from Abroad

Announcements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?